Abatacept
Antibody
Drugmakers mostly post higher profits, muted salesIt had sales of $5.49 billion, up nearly 5 percent. Abilify, Orencia for rheumatoid arthritis, leukemia drug Sprycel and hepatitis B drug Baraclude all had double-digit sales increases. Blood thinner Plavix, the world's No. 2 drug, had... In this article: Merck & Co., Schering-Plough Corp, Revenue, Bristol-Myers, Novartis AG, Januvia, Allergy, U.S., Recession, and Tax |
-
Centre Daily Times | October 21, 2009
Earnings Preview: Bristol-Myers 3Q earnings report
Meanwhile, she said investor focus remains on cost savings, sales of four growth drivers - Plavix, Orencia for rheumatoid arthritis, leukemia drug Sprycel and combination HIV drug Atripla - along with some key drugs in development. Those...
In this article: Bristol-Myers, Plavix, Revenue, Abilify, Food and Drug Administration, AstraZeneca PLC, Bristol, Ipilimumab, and Otsuka Pharmaceutical Co.
-
Seeking Alpha | October 22, 2009
Bristol-Myers Squibb Q3: Beats by a Penny
...million, up 33%, Schizophrenia drug Abilify came in at $653 million, up 16%, rheumatoid arthritis drug Orencia was at $162 million, up 36% and leukemia drug Sprycel reached $107 million, up 30%. However, cancer drug Erbitux generated sales...
In this article: Bristol-Myers Squibb, Revenue, Plavix, AstraZeneca plc, Bristol, Ipilimumab, LLY, Sanofi-Aventis, and Baraclude
-
Bristol-Myers posts higher 3Q sales, lower profit
Several Bristol-Myers drugs had double-digit sales jumps. Those included Abilify, Orencia for rheumatoid arthritis, leukemia drug Sprycel and hepatitis B drug Baraclude. The company also launched its newest drug, Onglyza for diabetes,...
In this article: Bristol-Myers, Revenue, Abilify, Bipolar disorder, Baraclude, Sprycel, Plavix, Reyataz, Leukemia, and Orencia
-
www.clinicaltrials.gov
Safety and Tolerability Trial of Abatacept-based ...
Immune phenotype of donor cells in patients receiving abatacept. ... Leukemia, Myeloid. Immunosuppressive Agents. Pharmacologic Actions. Neoplasms ...
-
www.docguide.com
News - Abatacept Linked to Slower Rate of Progression in ...
Abatacept Linked to Slower Rate of Progression in Patients With Inadequate ... Co-Existence of Acute Myeloid Leukemia with Multilineage Dysplasia and Epstein ...
-
News - Abatacept/Methotrexate Combo Reduces Progression of ...
Abatacept/Methotrexate Combo Reduces Progression of Rheumatoid Arthritis: ... Co-Existence of Acute Myeloid Leukemia with Multilineage Dysplasia and Epstein ...
-
www.mskreport.com
Musculoskeletal Report: Abatacept Wins Plaudits in Refractory JIA
Abatacept works more upstream and closer to the source of the disease than other ... The leukemia was diagnosed at day 89 in a patient who was anemic at enrollment ...
-
packageinserts.bms.com
FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND ...
The final concentration of abatacept in the bag or bottle ... study were infected with murine leukemia virus and mouse mammary tumor virus. ...
-
clinicaltrials.gov
ClinicalTrials.gov: "Leukemia" | received in the last 60 days
Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors ... and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of ...
Trends
Loading...
More on Abatacept
Description from Wikipedia:
Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy.
Explore everything named Abatacept...
